PLAINSBORO, N.J., Apr 27, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the introduction of INTEGRA(TM) Meshed Bilayer Wound Matrix, and will feature the product at the upcoming 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society Meeting, April 26-29, 2009, Dallas, Texas. INTEGRA(TM) Meshed Bilayer Wound Matrix has received 510(k) clearance from the Food & Drug Administration in the United States.

INTEGRA(TM) Meshed Bilayer Wound Matrix is an advanced bilayer wound management system, designed to provide immediate wound closure. Based on Integra's proven collagen technology, it is designed to be used with Negative Pressure Wound Therapy (NPWT) and allows drainage of wound exudate directly through the meshed matrix. NPWT, also known as vacuum assisted closure, is a technique of wound closure used to promote healing in large or chronic wounds and fight infection. A vacuum is used to reduce pressure around the wound, drawing out excess fluids and cellular wastes.

"This is an exciting new product for Integra and reflects our commitment to expand our portfolio of regenerative soft tissue and advanced wound care products," said Tom Tarca, Integra's VP of Marketing for the Extremity Reconstruction business. "We are especially pleased that we can now offer both patients and physicians a product specifically designed for use in negative pressure wound therapy."

The INTEGRA(TM) Meshed Bilayer Wound Matrix is comprised of a complex 3-dimentional porous collagen matrix and glycosaminoglycan and a semi-permeable silicone layer. The semi-permeable silicone layer controls water vapor loss and provides a flexible, adherent covering for the wound surface. The collagen-glycosaminoglycan matrix provides a scaffold for cell migration and capillary growth.

INTEGRA(TM) Meshed Bilayer Wound Matrix's many benefits include immediate wound coverage, high conformability, exceptional strength and flexibility, room temperature storage and long shelf life.

INTEGRA(TM) Meshed Bilayer Wound Matrix may be used for the management of chronic and traumatic wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic and vascular ulcers, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds.

There are currently 18 million people with diabetes in the U.S. Approximately 15% of those sustain one or more diabetic foot ulcers during their lifetime, and this population is also 15 times more likely to suffer an amputation due to non-healing diabetic foot ulcers. However, approximately 85% of all amputations are preventable if proper intervention is provided. According to industry sources, the cost of treating a diabetic ulcer may be as high as $28,000 over the two years following diagnosis. Approximately 500,000 adults seek treatment for venous leg ulcers annually in the United States. Integra estimates that the market opportunity in the U.S. for the meshed wound matrix is approximately $180 million.

INTEGRA(TM) Meshed Bilayer Wound Matrix will be sold by Integra's Extremity Reconstruction sales organization, which includes over 85 U.S. sales specialists focused on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of clinically relevant, innovative, and cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, orthopedics and general surgery, are used to treat millions of patients every year. The Company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information visit www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use INTEGRA(TM) Meshed Bilayer Wound Matrix may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART - P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
          Gianna Sabella, Director of Corporate Communications
          (609) 936-2389
          gsabella@Integra-LS.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX